Analysis of Stoke Therapeutics Options Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy STOK?
Source: NASDAQ.COM
- Options Selling Risk: Selling puts on Stoke Therapeutics does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The seller will only hold shares at a cost basis of $17.75 if Stoke's stock price falls by 33.7% and the contract is exercised, indicating stringent conditions for exercising the option.
- Annualized Return: The only upside for the put seller comes from collecting a 20.2% annualized return, suggesting that under current market conditions, the seller's profit primarily relies on the premium collected from the option.
- Volatility Consideration: With a trailing twelve-month volatility of 70% for Stoke Therapeutics, this metric, combined with fundamental analysis, can assist investors in assessing whether selling the put at a $20 strike price is a worthwhile risk-reward proposition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STOK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STOK
Wall Street analysts forecast STOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 35.75 USD with a low forecast of 25.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.480
Low
25.00
Averages
35.75
High
50.00
Current: 30.480
Low
25.00
Averages
35.75
High
50.00
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Stoke Therapeutics Options Trading
- Options Selling Risk: Selling puts on Stoke Therapeutics does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The seller will only hold shares at a cost basis of $17.75 if Stoke's stock price falls by 33.7% and the contract is exercised, indicating stringent conditions for exercising the option.
- Annualized Return: The only upside for the put seller comes from collecting a 20.2% annualized return, suggesting that under current market conditions, the seller's profit primarily relies on the premium collected from the option.
- Volatility Consideration: With a trailing twelve-month volatility of 70% for Stoke Therapeutics, this metric, combined with fundamental analysis, can assist investors in assessing whether selling the put at a $20 strike price is a worthwhile risk-reward proposition.
See More
Stoke Therapeutics Secures New Headquarters in Waltham
- New Headquarters: Stoke Therapeutics has secured a long-term lease for a 98,500 square-foot headquarters in Waltham, set to relocate by late 2026, marking a significant step in the development of its potential disease-modifying medicine, zorevunersen, for Dravet syndrome.
- Research Expansion: The new headquarters will bolster Stoke's research efforts in RNA medicine, particularly in preparing for the commercialization of zorevunersen, which is expected to provide the first potential new treatment for Dravet syndrome patients, enhancing the company's market position in the biotech sector.
- Market Resilience: Despite a national slowdown in the life sciences market, Waltham and its surrounding areas continue to demonstrate strong resilience, serving as a critical support for the biotech industry, reflecting the ongoing strength of the Greater Boston life sciences market.
- Sustainability Commitment: The new property is LEED Gold and WiredScore Platinum certified, showcasing Stoke's commitment to sustainability and modern infrastructure, aligning with the strategic needs for the company's future expansion.
See More
Stoke Therapeutics Secures New Headquarters in Waltham for Growth and Research Expansion
- New Headquarters: Stoke Therapeutics plans to relocate to a new 98,500 square-foot headquarters in Waltham by late 2026, aimed at supporting the commercialization of its first potential disease-modifying drug, zorevunersen, enhancing its market competitiveness in treating Dravet syndrome.
- Significant Lease: This lease represents one of the largest life sciences leases in the Greater Boston area over the past year, reflecting the resilience and continued growth potential of the region's life sciences market, further solidifying Waltham's status as a biotech hub.
- Research Expansion Plans: Stoke aims to leverage the new headquarters to foster teamwork and innovation, not only advancing zorevunersen through clinical trials but also expanding its research pipeline to develop more new medicines for severe diseases, enhancing the company's long-term growth potential.
- Sustainability Commitment: The new site is LEED Gold and WiredScore Platinum certified, demonstrating Stoke's commitment to operational efficiency and sustainability, ensuring a competitive edge in attracting top talent and meeting market demands.
See More
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
- Financial Performance Preview: Exelixis announced a preliminary US net product revenue of $2.123 billion for 2025, but the market reacted negatively, causing shares to drop 4.6% to $42.01 in pre-market trading, indicating investor caution regarding future performance.
- 2026 Outlook: The company projects net product revenue for 2026 to be between $2.325 billion and $2.425 billion, which, while optimistic, may not instill confidence in investors about achieving these targets, potentially impacting long-term growth expectations.
- Market Turbulence: Several stocks showed poor performance in pre-market trading, with Synchrony Financial down 9.5% to $78.61 and Stoke Therapeutics down 8.7% to $30.00, reflecting a generally bearish market sentiment possibly influenced by macroeconomic factors.
- Other Stock Movements: Capital One Financial and Bread Financial Holdings fell 8.4% and 8.3%, respectively, indicating that financial stocks are under pressure in the current market environment, prompting investors to closely monitor upcoming earnings reports for future trends.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Stoke Therapeutics Accelerates EMPEROR Study Timeline, Expects Patient Enrollment by Q2 2026
- Accelerated Research Timeline: Stoke Therapeutics announced that its pivotal Phase 3 EMPEROR study is expected to complete enrollment of 150 patients by Q2 2026, positioning the study for a data readout in mid-2027, which may support a New Drug Application submission.
- Regulatory Pathway Exploration: During a multidisciplinary meeting with the FDA, Stoke discussed opportunities for expedited development and registration of Zorevunersen, with the FDA requesting additional information to facilitate the drug's progress despite no immediate changes to the development plan.
- Patient Recruitment Status: As of January 9, 2026, nearly 330 patients globally have been identified as potential candidates for the EMPEROR study, with approximately 60 undergoing an 8-week formal screening and another 60 already randomized and dosed, indicating robust recruitment efforts.
- Strong Financial Position: As of December 31, 2025, Stoke reported approximately $391.7 million in cash and cash equivalents, and with proceeds from its collaboration with Biogen, the company expects to fund operations into 2028, reflecting its ongoing commitment to research and development.
See More
Analysis of Stoke Therapeutics Options Trading
- Options Selling Risk: Selling puts on Stoke Therapeutics does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The seller will only hold shares at a cost basis of $17.75 if Stoke's stock price falls by 33.7% and the contract is exercised, indicating stringent conditions for exercising the option.
- Annualized Return: The only upside for the put seller comes from collecting a 20.2% annualized return, suggesting that under current market conditions, the seller's profit primarily relies on the premium collected from the option.
- Volatility Consideration: With a trailing twelve-month volatility of 70% for Stoke Therapeutics, this metric, combined with fundamental analysis, can assist investors in assessing whether selling the put at a $20 strike price is a worthwhile risk-reward proposition.
See More
Stoke Therapeutics Secures New Headquarters in Waltham
- New Headquarters: Stoke Therapeutics has secured a long-term lease for a 98,500 square-foot headquarters in Waltham, set to relocate by late 2026, marking a significant step in the development of its potential disease-modifying medicine, zorevunersen, for Dravet syndrome.
- Research Expansion: The new headquarters will bolster Stoke's research efforts in RNA medicine, particularly in preparing for the commercialization of zorevunersen, which is expected to provide the first potential new treatment for Dravet syndrome patients, enhancing the company's market position in the biotech sector.
- Market Resilience: Despite a national slowdown in the life sciences market, Waltham and its surrounding areas continue to demonstrate strong resilience, serving as a critical support for the biotech industry, reflecting the ongoing strength of the Greater Boston life sciences market.
- Sustainability Commitment: The new property is LEED Gold and WiredScore Platinum certified, showcasing Stoke's commitment to sustainability and modern infrastructure, aligning with the strategic needs for the company's future expansion.
See More
Stoke Therapeutics Secures New Headquarters in Waltham for Growth and Research Expansion
- New Headquarters: Stoke Therapeutics plans to relocate to a new 98,500 square-foot headquarters in Waltham by late 2026, aimed at supporting the commercialization of its first potential disease-modifying drug, zorevunersen, enhancing its market competitiveness in treating Dravet syndrome.
- Significant Lease: This lease represents one of the largest life sciences leases in the Greater Boston area over the past year, reflecting the resilience and continued growth potential of the region's life sciences market, further solidifying Waltham's status as a biotech hub.
- Research Expansion Plans: Stoke aims to leverage the new headquarters to foster teamwork and innovation, not only advancing zorevunersen through clinical trials but also expanding its research pipeline to develop more new medicines for severe diseases, enhancing the company's long-term growth potential.
- Sustainability Commitment: The new site is LEED Gold and WiredScore Platinum certified, demonstrating Stoke's commitment to operational efficiency and sustainability, ensuring a competitive edge in attracting top talent and meeting market demands.
See More
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
- Financial Performance Preview: Exelixis announced a preliminary US net product revenue of $2.123 billion for 2025, but the market reacted negatively, causing shares to drop 4.6% to $42.01 in pre-market trading, indicating investor caution regarding future performance.
- 2026 Outlook: The company projects net product revenue for 2026 to be between $2.325 billion and $2.425 billion, which, while optimistic, may not instill confidence in investors about achieving these targets, potentially impacting long-term growth expectations.
- Market Turbulence: Several stocks showed poor performance in pre-market trading, with Synchrony Financial down 9.5% to $78.61 and Stoke Therapeutics down 8.7% to $30.00, reflecting a generally bearish market sentiment possibly influenced by macroeconomic factors.
- Other Stock Movements: Capital One Financial and Bread Financial Holdings fell 8.4% and 8.3%, respectively, indicating that financial stocks are under pressure in the current market environment, prompting investors to closely monitor upcoming earnings reports for future trends.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Stoke Therapeutics Accelerates EMPEROR Study Timeline, Expects Patient Enrollment by Q2 2026
- Accelerated Research Timeline: Stoke Therapeutics announced that its pivotal Phase 3 EMPEROR study is expected to complete enrollment of 150 patients by Q2 2026, positioning the study for a data readout in mid-2027, which may support a New Drug Application submission.
- Regulatory Pathway Exploration: During a multidisciplinary meeting with the FDA, Stoke discussed opportunities for expedited development and registration of Zorevunersen, with the FDA requesting additional information to facilitate the drug's progress despite no immediate changes to the development plan.
- Patient Recruitment Status: As of January 9, 2026, nearly 330 patients globally have been identified as potential candidates for the EMPEROR study, with approximately 60 undergoing an 8-week formal screening and another 60 already randomized and dosed, indicating robust recruitment efforts.
- Strong Financial Position: As of December 31, 2025, Stoke reported approximately $391.7 million in cash and cash equivalents, and with proceeds from its collaboration with Biogen, the company expects to fund operations into 2028, reflecting its ongoing commitment to research and development.
See More
